



## **Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference**

April 10, 2023

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22<sup>nd</sup> Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com). An archived webcast recording will be available on the Cara website for approximately 30 days.

### **About Cara Therapeutics**

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company's KORSUVA<sup>®</sup> (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com) and follow the company on [Twitter](#), [LinkedIn](#) and [Instagram](#).

### **MEDIA CONTACT:**

Annie Spinetta  
6 Degrees  
973-768-2170  
[aspinetta@6degreespr.com](mailto:aspinetta@6degreespr.com)

### **INVESTOR CONTACT:**

Iris Francesconi, Ph.D.  
Cara Therapeutics  
203-406-3700  
[investor@caratherapeutics.com](mailto:investor@caratherapeutics.com)



Source: Cara Therapeutics, Inc.